Introduction: This research evaluates the treatment benefits of platelet-rich plasma (PRP) and erythropoietin (EPO) on diabetic nephropathy and hepatopathy in rats. Methods: Thirty male rats were separated into five groups: control, diabetic control, PRPtreated diabetic (1 mL PRP subcutaneously twice weekly), EPO-treated diabetic (300 units/ kg EPO subcutaneously three times weekly), and a combination of PRP and EPO treatment (1 mL PRP twice weekly and 300 units/kg EPO three times weekly). Diabetes was induced using streptozotocin (65 mg/kg), and treatments were administered over four weeks. Serum markers for renal and hepatic function, oxidative stress indices, and histopathological changes in liver and kidney tissues were assessed.
Results: In diabetic rats, serum urea, creatinine, and liver enzymes (ALT, AST, ALP, LDH, GGT) increased significantly (p0.05). Renal and hepatic SOD decreased significantly in diabetes (p0.05). Damage in kidney and liver tissues were obtained in diabetic group. Histopathological improvements were evident, in hepatocyte integrity and glomerular structure, with EPO and PRP treatments.
Conclusion: The results emphasize the potential of EPO and PRP as complementary therapeutic strategies to reduce diabetes-induced oxidative damage and structural deterioration in liver and kidney tissues. However, further adjunctive approaches are required to achieve comprehensive organ protection